Kurita, Naoki http://orcid.org/0000-0002-1283-4307
Nishikii, Hidekazu
Maruyama, Yumiko
Suehara, Yasuhito
Hattori, Keiichiro
Sakamoto, Tatsuhiro
Kato, Takayasu
Yokoyama, Yasuhisa
Obara, Naoshi
Maruo, Kazushi
Ohigashi, Tomohiro
Yamaguchi, Hitomi
Iwamoto, Toshiro
Minohara, Hideto
Matsuoka, Ryota
Hashimoto, Koichi
Sakata-Yanagimoto, Mamiko
Chiba, Shigeru
Article History
Received: 30 January 2023
Accepted: 8 August 2023
First Online: 17 August 2023
Declarations
:
: The study was approved by the institutional review board of University of Tsukuba Hospital (approval #I-27). UMIN Clinical Trials Registry identifier: UMIN000033799.
: Written informed consent was obtained from all patients in accordance with the Declaration of Helsinki.
: The study was sponsored by Kyowa Kirin Co., Ltd., which provided the study drug to the participants free of charge. The authors declare that no funding or sponsoring agency played any role in the study design, patient enrollment, data acquisition/analysis, manuscript drafting, or the decision to publish this study. MS-Y received research funding from Eisai, Bristol Myers Squibb, and Otsuka. SC received research funding from Kyowa Kirin, Chugai, Ono, Astellas, Beyer, Eisai, and Thyas. The other authors have no conflict of interest to declare.